Reversal of myeloid cell - mediated immunosuppression in patients with metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8270-8278

  Kusmartsev, Sergei ^a   Su, Zhen ^a   Heiser, Axel ^a   Dannull, Jens ^b   Eruslanov, Evgeniy ^a   Kübler, Hubert ^a   Yancey, Donna ^b   Dahm, Philip ^a   Vieweg, Johannes ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; DIFFERENTIATION ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAGNETIC SEPARATION; METASTASIS; PRIORITY JOURNAL; STEM CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KIDNEY TUMOR; PHYSIOLOGY;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, RENAL CELL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; KIDNEY NEOPLASMS; MYELOID CELLS; TRETINOIN;

EID: 58149332680     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0165     Document Type: Article

References (34)

1. Rosenberg SA,Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2005;10:909-15.
2. Deerwish IH,Tannebaum CS, Rayman PA, Finke JH. Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat Res 2003;116:29 -51.
3. Vieweg J, Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther 2004;4:1791 -801.
4. Young MRI, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-b and nitric oxide. J Immunol 1996;156:1916-21.
5. Gabrilovich D, Ishida T, Oyama T, et al.Vascularendothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.Blood 1998;92:4150-66.
6. Kusmartsev S, Kusmartseva I, Afanasyev SG, Cherdyntseva NV. Immunosuppressive cells in bone marrow of patients with stomach cancer. Adv Exp Med Biol 1998;451:189-94.
7. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37.
8. Kusmartsev S, Li Y, Chen SH. Gr-1 + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 co-stimulation. JImmunol 2000;165:779-85.
9. Melani C, Chiodoni C, Forni G, Colombo MP.Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003;102:2138-45.
10. Rodriguez PC, Hernandez CP, David Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202:931 -9.
11. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507-13.
12. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3ζ expression by L-arginine. J Biol Chem 2002;277:21123-9.
13. Bronte, erafini P, e Santo C, et al. L-4-induced arginase 1 suppresses alloreactive cells in tumorbearing mice. J Immunol 2003;170:270-8.
14. Zea A, Rodriguez P, Atkins M, et al. Arginase- producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
15. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide aretheunder- lying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61: 4756 -60.
16. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003;74:186 -96.
17. + immature myeloid suppressor cells mediate the development of tumor-induced Tregulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123 -31.
18. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92.
19. + T cell tolerance in cancer. Nat Med 2007;13:828-35.
20. + Tcell responses in patients with metastatic prostate cancer. J Immunol 2005;174: 3798-807.
21. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
22. Almand B, Clark J, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
23. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989-99.
24. Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, Subiza JL. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-ä. J Immunol 1995;155:15-26.
25. Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002;168: 689-95.
26. Liu Y,Van Ginderachter J, Brys L, De Baetselier P, Raes G, Geldhof A. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003;170:5064-74.
27. Itoh Y, Ma FH, Hoshi H, et al. Determination andbioimaging method for nitric oxide in biological specimens by diaminofluorescein fluorometry. Anal Biochem 2000;287:203 -9.
28. BreitmanTR, Chen ZX,Takahashi N. Potential applications of cytodifferentiation therapy in hematologic malignancies. Semin Hematol 1994;31:18-25.
29. Mirza N, Fishman M, Fricke I, et al. A//-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66:9299 -307.
30. Kusmartsev S, Cheng F,Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor- bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441 -9.
31. Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape. Cancer Immunol Immunother 2004;53:879 -92.
32. RivoltiniL,CarrabbaM,HuberV,etal.Immunityto cancer: attack and escape inT lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113.
33. ViewegJ, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-induced immune suppression. Clin Cancer Res 2007;13:727-32.
34. BronteV, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1 (+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) Tcells. Blood 2000;96:3838.